Leukemia Research
Volume 29, Issue 2 , Pages 165-171 , February 2005

Detection of hemizygous deletions in genomic DNA from leukaemia specimens for the diagnosis of patients

  • Ursula R. Kees

      Affiliations

    • Telethon Institute for Child Health Research, and Centre for Child Health Research, The University of Western Australia, Perth, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 8 9489 7852; fax: +61 8 9489 7700.
    • ,
  • Philippa A. Terry

      Affiliations

    • Telethon Institute for Child Health Research, and Centre for Child Health Research, The University of Western Australia, Perth, Australia
    • ,
  • Jette Ford

      Affiliations

    • Telethon Institute for Child Health Research, and Centre for Child Health Research, The University of Western Australia, Perth, Australia
    • ,
  • Janet Everett

      Affiliations

    • Pathology, Women's and Children's Health Service, Perth, Australia
    • ,
  • Ashleigh Murch

      Affiliations

    • Pathology, Women's and Children's Health Service, Perth, Australia
    • ,
  • Nick de Klerk

      Affiliations

    • Telethon Institute for Child Health Research, and Centre for Child Health Research, The University of Western Australia, Perth, Australia
    • ,
  • David L. Baker

      Affiliations

    • Department of Haematology–Oncology, Princess Margaret Hospital, Perth, Australia

Received 5 February 2004 ,Accepted 14 May 2004.

References 

  1. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985;45:1437–1443
  2. Cook WD, McCaw BJ. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene. 2000;19:3434–3438
  3. Fodde R, Smits R. A matter of dosage. Science. 2002;298:761–763
  4. Goss KH, Risinger MA, Kordich JJ, Sanz MM, Straughen JE, Slovek LE, et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science. 2002;297:2051–2053
  5. Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, et al. BLM heterozygosity and the risk of colorectal cancer. Science. 2002;297:2013
  6. Carter TL, Watt PM, Kumar R, Burton PR, Reaman GH, Sather HN, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood. 2001;97:572–574
  7. Kees UR, Ford J, Price PJ, Meyer BF, Herrmann RP. PER-117: a new human ALL cell line with an immature thymic phenotype. Leuk. Res. 1987;11:489–498
  8. Kees UR, Ford J, Watson M, Murch A, Ringner M, Walker RL, et al. Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease. Mol. Cancer Ther. 2003;2:671–677
  9. Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 1997;89:4161–4166
  10. Webber LM, Garson OM. Fluorodeoxyuridine synchronization of bone marrow cultures. Cancer Genet. Cytogenet. 1983;8:123–132
  11. Kees UR, Lukeis R, Ford J, Willoughby ML, Garson OM. Establishment and characterization of a childhood pre-B acute lymphoblastic leukemia cell line, PER-278, with chromosome translocations t(1;19) and t(1;9). Cancer Genet. Cytogenet. 1990;46:201–208
  12. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537
  13. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffiuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  14. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Cancer Res. 1996;68:67–108
  15. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845–859
  16. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16INK4A contributes to the outcome of cancer therapy. Cell. 2002;109:335–346
  17. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H, et al. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2003;37:44–57
  18. Lund AH, Turner G, Trubetskoy A, Verhoeven E, Wientjens E, Hulsman D, et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat. Genet. 2002;32:160–165
  19. Zhai S, Senderowicz AM, Sausville EA, Figg WD. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother. 2002;36:905–911
  20. Quon KC, Berns A. Haplo-insufficiency? Let me count the ways. Genes Dev. 2001;15:2917–2921
  21. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am. J. Pathol. 2001;159:359–367
  22. Kwabbi-Addo B, Giri D, Schmidt K, Podsypaninia K, Parsons R, Greenberg N, et al. Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. U.S.A. 2001;98:11563–11568
  23. Carter TL, Terry PA, Gottardo N, Baker DL, Kees UR, Watt PM. Deletion of one copy of the p16INK4A tumor suppressor gene is implicated as a predisposing factor in pediatric leukemia. Biochem. Biophys. Res. Commun. 2004;318:852–855
  24. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185–197

PII: S0145-2126(04)00234-6

doi: 10.1016/j.leukres.2004.05.021

Leukemia Research
Volume 29, Issue 2 , Pages 165-171 , February 2005

Article Tools

* Image Usage & Resolution